Top 5 Performing Stocks To Buy Right Now

With Dow 22,000 alerting Main Street investors to the fact stocks are at record highs, its a good time to reiterate that August has been the worst-performing month for the Dow the past 20 years. The Dow has fallen 1.4%, on average, in August and finished up just 50% of the time.

So what events in August could derail the Dows record run? LPL Financials chief wealth strategist Matthew Peterson and senior market strategist Ryan Detrick compiled a watch list:

Jobs report: The July employment report will be released Friday. Wall Street is looking for a continuation of the upbeat report in June, when the economy created 222,000 jobs. LPL is expecting 180,000 new jobs in August.

Inflation update: The Federal Reserve has hiked interest rates twice this year. But tepid inflation in recent months has complicated its future hike plans. On Aug. 11, investors will get a look at July inflation at the consumer level. If it is weak and stays south of the Feds 2% goal, the rate-hike schedule could be pushed back.

Top 5 Performing Stocks To Buy Right Now: MV Oil Trust(MVO)

Advisors’ Opinion:

  • [By Max Byerly]

    MV Oil Trust (NYSE: MVO) and Petroleo Brasileiro SA Petrobras (NYSE:PBR.A) are both oils/energy companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

Top 5 Performing Stocks To Buy Right Now: Equus Total Return, Inc.(EQS)

Advisors’ Opinion:

  • [By Anders Melin]

    Taking that a step further, you can run searches on the Equity Screening (EQS) function using the new pay metrics or data on say-on-pay, which refers to shareholders’ right to vote on management remuneration. To see Russell 1000 companies with the lowest support on pay, for example, go to {EQS <GO>}. In the Add Criteria field, enter RIY and click on the Russell 1000 Index match. Next, enter Say on Pay, click on the Say on Pay Support Level item, and press <GO>. Click on the See Results | WATC button for a list of companies in the benchmark that you can sort by the percentage of shareholders supporting management on pay.

Top 5 Performing Stocks To Buy Right Now: NovoCure Limited(NVCR)

Advisors’ Opinion:

  • [By Brian Feroldi]

    After the company reported first-quarter results, shares of NovoCure (NASDAQ:NVCR), a medical device company focused on cancer, jumped as much as 10% in afternoon trading on Thursday. Shares closed the day up more than 9%.

  • [By Todd Campbell, Sean Williams, and Brian Feroldi]

    There have been more stock market pops and drops lately and that might have you wondering what healthcare stocks can be bought to take advantage of this volatility. Buying healthcare stocks during periods of volatility can be smart because demand for healthcare products and services usually isn’t discretionary. However, that doesn’t necessarily mean it makes sense to buy every healthcare stock out there. To find out what healthcare stocks it might make sense to buy this month, we asked top Motley Fool investors what companies are on their radar. In their view,Teva Pharmaceutical Industries (NYSE:TEVA), Novacure (NASDAQ:NVCR), and Galapagos (NASDAQ:GLPG)should be at the top of your idea list right now. Read on to find out why.

  • [By Lee Jackson]

    This stock has been on a roll and looks ready to break out. NovoCure Ltd. (NASDAQ: NVCR) develops and commercializes treatments for solid tumor cancer therapy called the tumor treating fields (TTFields). Its markets its proprietary TTFields delivery system under the Optune name for use as a monotherapy treatment for adult patients with glioblastoma brain cancer.

  • [By Chris Lange]

    NocoCure Ltd. (NASDAQ: NVCR) is scheduled to release its fourth-quarter earnings report on February 22 as well. The consensus estimates call for a net loss of $0.11 per share and $53.52 million in revenue. The same period of last year had a net loss of $0.26 per share and $30.24 million in revenue. Shares of Novocure most recently closed at $21.50, with a consensus price target of $27.00 and a 52-week range of $6.75 to $24.15.

Top 5 Performing Stocks To Buy Right Now: ANI Pharmaceuticals, Inc.(ANIP)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Canaccord Genuity set a $82.00 target price on ANI Pharmaceuticals (NASDAQ:ANIP) in a research report released on Tuesday morning. The firm currently has a buy rating on the specialty pharmaceutical company’s stock.

Top 5 Performing Stocks To Buy Right Now: Blue Capital Reinsurance Holdings Ltd.(BCRH)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Here are some of the headlines that may have impacted Accern’s rankings:

    Get Akari Therapeutics alerts:

    Akari Therapeutics, Plc (AKTX) Analysts See $-1.00 EPS; HC INTERNATIONAL ORDINARY SHARES CA (HCINF … (mtastar.com) Trader’s Buzzers- Boxlight Corporation (NASDAQ:BOXL), Blue Capital Reinsurance Holdings Ltd. (NYSE:BCRH), Akari … (journalfinance.net) Akari Therapeutics (AKTX) Lifted to “Hold” at ValuEngine (americanbankingnews.com) Guillain-Barre Syndrome Market to reach value of US$ 708.6 Mn by 2025, Says TMRGlobal GuillainBarre Syndrome … (markets.businessinsider.com) Analysts See $-1.00 EPS for Akari Therapeutics, Plc (AKTX); Verastem (VSTM) SI Decreased By 7.78% (mtastar.com)

    Several brokerages have commented on AKTX. ValuEngine upgraded Akari Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday. Canaccord Genuity cut their target price on Akari Therapeutics from $15.00 to $8.00 and set a “buy” rating for the company in a research note on Thursday, March 29th. B. Riley began coverage on Akari Therapeutics in a research note on Thursday, February 8th. They issued a “neutral” rating and a $3.00 target price for the company. Finally, Zacks Investment Research downgraded Akari Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 16th. Four analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $4.63.

  • [By Shane Hupp]

    Blue Capital Reinsurance (NYSE:BCRH) reached a new 52-week high and low during trading on Thursday . The company traded as low as $10.90 and last traded at $11.05, with a volume of 17133 shares trading hands. The stock had previously closed at $11.20.